| Identification | Back Directory | [Name]
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenoxypent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide | [CAS]
1421369-12-1 | [Synonyms]
17-phenoxy trinor PGF2αethyl amide
17-phenoxy trinor Prostaglandin F2α ethyl amide
17-phenoxy trinor Prostaglandin F2.alpha. ethyl amide
17-phenoxy trinor Prostaglandin F2α ethyl amide Exclusive
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenoxypent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
5-Heptenamide, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenoxy-1-penten-1-yl]cyclopentyl]-N-ethyl-, (5Z)- | [Molecular Formula]
C25H37NO5 | [MDL Number]
MFCD18427984 | [MOL File]
1421369-12-1.mol | [Molecular Weight]
431.57 |
| Hazard Information | Back Directory | [Description]
Prostaglandin F2α (PGF2α), acting through the FP receptor, causes smooth muscle contraction and exhibits potent luteolytic activity. Both 17-phenyl trinor PGF2α and 16-phenoxy tetranor PGF2α are metabolically stable analogs of PGF2α and potent agonists for the FP receptor. 17-phenoxy trinor PGF2α ethyl amide is a lipophilic analog of 17-phenoxy trinor PGF2α . Ethyl amides of PGs serve as prodrugs, as they are hydrolyzed in certain tissues to generate the bioactive free acid. | [Uses]
17-Phenoxy trinor prostaglandin F2α ethyl amide (17-Phenoxy trinor PGF2α ethyl amide) is an analog of Bimatoprost (HY-12956). 17-Phenoxy trinor prostaglandin F2α ethyl amide is an agonist for Prostaglandin F2α Receptor (FP receptor). 17-Phenoxy trinor prostaglandin F2α ethyl amide is potent to reduce the intraocular pressure and attenuate the glaucoma[1][2]. | [References]
[1] Balapure AK, et al., Structural requirements for prostaglandin analog interaction with the ovine corpus luteum prostaglandin F2 alpha receptor. Implications for development of a photoaffinity probe. Biochem Pharmacol. 1989 Jul 15;38(14):2375-81. DOI:10.1016/0006-2952(89)90478-4
[2] Woodward DF, et al., Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther. 2003 May;305(2):772-85. DOI:10.1124/jpet.102.047837 |
|
|